Table 2.
Baseline characteristics (at enrollment) of the pediatric MS cases and controls and subsequent follow‐up for cases (targeted tryptophan analysis)
| TRP1 set (Discovery) | TRP2 set (Replication) | |||||
|---|---|---|---|---|---|---|
| Cases | Control | P‐value1 | Cases | Controls | P‐value1 | |
| N | 82 | 50 | 92 | 50 | ||
| Age, mean (SD) | 13.4 (3.5) | 15.1 (2.8) | 0.004 | 12.6 (4.5) | 14.5 (2.9) | 0.01 |
| Female (%) | 56 (68%) | 27 (54%) | 0.10 | 62 (67%) | 17 (34%) | <0.001 |
| Race/ethnicity (%) | ||||||
| White, non‐Hispanic | 24 (29%) | 26 (52%) | 24 (26%) | 29 (58%) | ||
| White, Hispanic | 34 (41%) | 16 (32%) | 0.035 | 42 (46%) | 13 (26%) | 0.002 |
| Black | 6 (7%) | 4 (8%) | 7 (8%) | 1 (2%) | ||
| Others | 18 (22%) | 4 (8%) | 19 (21%) | 7 (14%) | ||
| Trp in mcg/mL, mean (SD) | 11.0 (2.3) | 12.3 (2.4) | 0.003 | 10.3 (2.6) | 12.1 (2.2) | <0.001 |
| 25(OH) vitamin D, ng/mL, mean (SD) | 24.6 (9.8) | 23.7 (7.3) | 0.57 | 24.2 (10.8) | 22.8 (10.2) | 0.43 |
| DMT exposed (%) | 66 (80%) | N/A | – | 69 (76%) | N/A | – |
| Follow‐up duration (from baseline to study end), years, mean (SD) | 3.5 (1.7) | N/A | – | 3.5 (2.3) | N/A | – |
| Median EDSS (IQR) | 3 (2–4) | N/A | – | 3 (2–4) | N/A | – |
| Mean SDMT (SD) | 51.3 (13.2) [62 out 82 patients had scores available] | N/A | – | 45.7 (13.2) [13 out of 92 patients had scores available] | ||
Trp, tryptophan; DMT, disease‐modifying therapy.
1Student T‐test for continuous variables and chi‐square test for categorical variables.